Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib

被引：7

作者：

Avery, S

Nadal, E

Marin, D

Olavarria, E

Kaeda, J

Vulliamy, T

Babapulle, FB

Goldman, JM

Apperley, JF

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Haematol, London W12 0NN, England

[2] Royal Berkshire Hosp, Dept Haematol, Reading RG1 5AN, Berks, England

来源：

LEUKEMIA RESEARCH | 2004年 / 28卷

关键词：

CML; lymphoid transformation; cytogenetic response; imatinib;

D O I：

10.1016/j.leukres.2003.10.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We describe here a patient with Philadelphia (Ph) chromosome-positive chronic myeloid leukemia who achieved a complete cytogenetic response following treatment with imatinib and then progressed abruptly to lymphoid blastic transformation. The sequence of events suggests that at least in some cases patients who respond well to imatinib may still harbor residual leukemia progenitor or 'stem' cells that are susceptible to acquisition of molecular events that underlie progression to advanced phase disease. The case highlights the need for molecular monitoring of responders and the need to develop strategies for reducing to a minimum or totally eradicating leukemia cells. (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：S75 / S77

页数：3

共 8 条

[1] Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment [J].

Bhatia, R ;

Holtz, M ;

Niu, N ;

Gray, R ;

Snyder, DS ;

Sawyers, CL ;

Arber, DA ;

Slovak, ML ;

Forman, SJ .

BLOOD, 2003, 101 (12) :4701-4707

[2]

Bose S, 1997, ACTA HAEMATOL-BASEL, V98, P155

[3] RELAPSE INTO BLAST CRISIS FOLLOWING BONE-MARROW TRANSPLANTATION FOR CHRONIC PHASE CHRONIC MYELOID-LEUKEMIA - A REPORT OF 5 CASES [J].

CULLIS, JO ;

MARKS, DI ;

SCHWARER, AP ;

BARRETT, AJ ;

HOWS, JM ;

SWIRSKY, DM ;

GOLDMAN, JM .

BRITISH JOURNAL OF HAEMATOLOGY, 1992, 81 (03) :378-382

[4] Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro [J].

Graham, SM ;

Jorgensen, HG ;

Allan, E ;

Pearson, C ;

Alcorn, MJ ;

Richmond, L ;

Holyoake, TL .

BLOOD, 2002, 99 (01) :319-325

[5] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia [J].

Hughes, TP ;

Kaeda, J ;

Branford, S ;

Rudzki, Z ;

Hochhaus, A ;

Hensley, ML ;

Gathmann, I ;

Bolton, AE ;

van Hoomissen, IC ;

Goldman, JM ;

Radich, JP ;

Taylor, K ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Lechner, K ;

Verhoef, G ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shepherd, J ;

Shustik, C ;

Lipton, J ;

Kovacs, DM ;

Turner, AR ;

Nielsen, JL ;

Birgens, H ;

Bjerrum, OW ;

Guilhot, F ;

Reiffers, J ;

Rousselot, P ;

Facon, T ;

Harousseau, JL ;

Tulliez, M ;

Guerci, A ;

Blaise, D ;

Maloisel, F ;

Michallet, M ;

Fischer, T ;

Hossfeld, D ;

Mertelsmann, R ;

Andreesen, R ;

Nerl, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) :1423-1432

[6] Paroxysmal nocturnal haemoglobinuria: Nature's gene therapy? [J].

Johnson, RJ ;

Hillmen, P .

JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 2002, 55 (03) :145-152

[7] Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia [J].

Kaeda, J ;

Chase, A ;

Goldman, JM .

ACTA HAEMATOLOGICA, 2002, 107 (02) :64-75

[8] Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia [J].

O'Brien, SG ;

Guilhot, F ;

Larson, RA ;

Gathmann, I ;

Baccarani, M ;

Cervantes, F ;

Cornelissen, JJ ;

Fischer, T ;

Hochhaus, A ;

Hughes, T ;

Lechner, K ;

Nielsen, JL ;

Rousselot, P ;

Reiffers, J ;

Saglio, G ;

Shepherd, J ;

Simonsson, B ;

Gratwohl, A ;

Goldman, JM ;

Kantarjian, H ;

Taylor, K ;

Verhoef, G ;

Bolton, AE ;

Capdeville, R ;

Druker, BJ ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shustik, C ;

Lipton, J ;

Forrest, D ;

Walker, I ;

Roy, DC ;

Rubinger, M ;

Bence-Bruckler, I ;

Kovacs, M ;

Turner, AR ;

Birgens, H ;

Bjerrum, O ;

Facon, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (11) :994-1004

← 1 →